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Active targeting of gold nanoparticles
as cancer therapeutics
Zoë Rachael Goddard, a Marı́a J. Marı́n, b David A. Russell b and
Mark Searcey *a
Gold nanoparticles (AuNPs) are of increasing interest for their unique properties and their
biocompatability, minimal toxicity, multivalency and size tunability make them exciting drug carriers. The
functionalisaton of AuNPs with targeting moieties allows for their selective delivery to cancers, with
antibodies, proteins, peptides, aptamers, carbohydrates and small molecules all exploited. Here, we
review the recent advances in targeted-AuNPs for the treatment of cancer, with a particular focus on
these classes of targeting ligands. We highlight the benefits and potential drawbacks of each ligand class
and propose directions in which the field could grow.
1. Introduction
Over 100 years ago, Paul Ehrlich described the concept of a
‘magic bullet’ for chemotherapy, in which drugs can be delivered
directly to their desired target, removing devastating off-target
effects.1,2 While there are many ways to go about the development
of a ‘magic bullet’, one such method is the combination of
nanotechnology and nanomedicine, an emerging field of cancer
therapeutics involving sub-one hundred nanometre delivery
vehicles (1–100 nm) to transport the desired therapeutic to its
target. Nanomedicine involves the use of nanoparticles, with
their nanoscale size providing significantly altered physical,
chemical and biological properties from that of the bulk
material, with these altered properties favourable for their use
as delivery vehicles.
Nanoparticles have been shown to display passive targeting
towards tumours through the enhanced permeability and reten-
tion (EPR) effect (Fig. 1).3 The EPR effect occurs due to the fact
that tumours have a high demand for blood flow to provide the
necessary nutrients and oxygen for their uncontrolled cell growth.
As they rapidly expand in size, tumours form new blood vessels to
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provide for this excess need, and these blood vessels tend to be
poorly formed and ‘leaky’. As nanoparticles are relatively large in
size compared to natural small molecules and growth factors, they
rarely pass through the walls of properly formed blood vessels in
normal tissue. The leaky vasculature in tumours, however, allows
for the passage of nanoparticles through their walls and leads to
an accumulation of nanoparticles within the tumour. Tumours
also display poor lymphatic drainage meaning that the nano-
particles that pass through into the tumour via the leaky blood
vessels are not carried away as efficiently from cancerous tissue as
from normal tissue, increasing this accumulation in tumours.
This passive accumulation of nanoparticles in cancerous tissues
highlights their ability to act as ‘magic bullets’.
A second benefit of nanoparticles is their large surface area
to volume ratio, meaning that one nanoparticle can carry a
large quantity of a payload to their target, providing an attrac-
tive method for drug delivery. This large surface area also
allows for the attachment of multiple different payloads to one
nanoparticle,4 allowing for their co-delivery to a target, which
has many therapeutic benefits. Diagnostic tools can also be
attached to nanoparticles alongside payloads to elicit a thera-
nostic effect, where the nanoparticle system can be used to
diagnose and treat cancers simultaneously.5,6 Nanoparticles
have been seen to improve stability, solubility and circulatory
half-lives of drugs, along with improved drug efficacy.7–9 They
have also been designed to release their payload upon inter-
nalisation into cancerous cells due to an internal stimulus such
as pH or a reducing environment, restricting drug release to
within cancer cells and improving the pharmacokinetics of a
drug.10,11 The benefits of nanoparticle delivery systems high-
light their applicability for the delivery of payloads to cancerous
tissue.
Many types of nanoparticle have been developed for drug
delivery, including liposomes,12 polymeric nanoparticles,13 carbon
dots,14 upconverting nanoparticles15 and inorganic nano-
particles.16 Inorganic structures include gold, silica and iron
oxide nanoparticles and quantum dots.16 While these all have
their benefits, gold nanoparticles (AuNPs) highlight themselves
as ideal drug carriers; they are chemically inert and minimally
toxic, meaning they can pass through the body without eliciting
any adverse reactions.17,18 For intravenous use as drug carriers,
AuNPs are often coated in a layer of polyethylene glycol (PEG)
ligands. PEG is clinically approved for intravenous use and
its amphiphilic nature stabilises nanoparticles within bio-
logical media, making AuNPs dispersible within aqueous
environments.19 PEG also increases the circulatory half-life of
AuNPs by blocking the adsorption of opsonins and serum
proteins, which enable the uptake and clearance of nano-
particles through the reticuloendothelial system.19–21 AuNPs
are non-porous nanoparticles, and as such they are commonly
loaded with payloads through chemical bonding or adsorption
to the surface ligands of the AuNPs.
The surface of AuNPs is easily functionalised through the
formation of strong gold–sulphur (Au–S) bonds that will spon-
taneously form through thiol surface adsorption.22 Au–S bonds
are non-labile and result in AuNPs that are stable to physio-
logically relevant pH and salt concentrations.23 The synthesis of
Fig. 1 The passive targeting of nanoparticles towards tumours through
the EPR effect.
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AuNPs involves the reduction of Au(III) to Au(0), which initiates
the nucleation of AuNPs. Tight control over the reaction con-
ditions means that the size and shape of AuNPs can be selected
and varied to fit the desired purpose.24 Different nanostructures
are beneficial for different purposes, and their uptake and
potential therapeutic properties vary from shape to shape.25 The
ability to form these different structures is a benefit of AuNPs and
this is not as achievable with other nanosystems. The synthesis of
AuNPs of differing shapes, such as nanosquares, nanostars
(AuNSs) and nanorods (AuNRs) is usually completed through a
seeded growth method.26 Here, small AuNPs are synthesised,
generally 4–5 nm in size, and the addition of these seeds to
Au(III) solutions containing different reducing and capping agents
can influence the shape of the nucleated nanosystems.27
The strength of the reducing agent has a strong influence on
the size of the AuNPs produced.28 For example, the use of a
strong reducing agent such as sodium borohydride (NaBH4)
results in sub-10 nm AuNPs, whereas for larger AuNPs milder
reducing agents such as trisodium citrate or ascorbic acid are
commonly used.28,29 The synthesis of AuNPs also relies on the
presence of a stabilising agent, and the choice of stabilising
agent can influence the size and shape of the resulting AuNPs
through steric hindrance, and reduce the polydispersity of the
synthesised AuNPs.30–32 For example, the addition of thiolated
ligands upon reduction of Au(III) leads to the formation of
strong Au–S bonds that cap the nanoparticles at a small and
relatively monodisperse size, but control over the gold : ligand
ratio determines the exact size of the AuNPs synthesised.33
While it is known that the size and shape of AuNPs can affect
their uptake in cells,34,35 this review will focus on the ligands
used for active targeting and not the effect of the core itself.
Due to the lack of degradation of AuNPs in vivo, particular care
must be taken when choosing the size of the core and the
surface ligands to avoid organ toxicity. AuNPs can accumulate
in the liver, spleen and lymph nodes if not correctly functiona-
lised to allow filtration by the reticuloendothelial system. The
pharmacokinetics of AuNPs have been reviewed elsewhere36
and are beyond the scope of this review.
AuNPs display a strong surface plasmon absorption due to the
oscillation of electrons upon exposure to light. AuNPs absorb
visible light with extinction coefficients orders of magnitude
higher than those of many strongly absorbing organic dyes, and
this surface plasmon absorption band is dependent on the size
and shape of the AuNPs.37 The presence of this surface plasmon
absorption band provides a unique property to AuNPs as the
strong absorption of light means that the nanoparticle itself can
be used as a therapeutic agent. When AuNPs are irradiated with
light matching the wavelength of their surface plasmon absorp-
tion band they rapidly heat and can destroy cells through photo-
thermal ablation, known as photothermal therapy (PTT).38
The biocompatibility, minimal cytotoxicity, stability, ease of
synthesis and functionalisation, passive targeting and the
unique surface plasmon properties of AuNPs highlight their
exciting potential as delivery systems for cancer therapeutics.
While passive targeting of AuNPs relying on the EPR effect
has been explored,39–42 as the interest in personalised medicine
has grown in recent years, the focus has turned towards the
active targeting of gold nanoparticles to a particular site. Active
targeting of AuNPs involves the attachment of a targeting
moiety, specific towards a desired surface receptor, onto the
nanoparticle surface, alongside the payload. In cancer, the
targeting moiety used often recognises a receptor that is over-
expressed by tumour cells, but examples also exist of AuNPs
targeted towards receptors that are cryptic or not expressed
on healthy cells. A plethora of targeting moieties have been
explored and these can be split into the general categories of
antibodies, proteins, peptides, aptamers, carbohydrates and
small molecules.
While there are many reviews highlighting the benefits of
targeted AuNPs, this review describes the recent progress
towards the utilisation of each class of targeting moiety with
respect to cancer therapeutics with the aim of collating these
targeting moieties to determine the benefits of each class of
ligands for targeted-AuNP therapies.
2. Antibody directed gold
nanoparticles
2.1 IgG antibodies
When the idea of actively targeting nanoparticles towards a
known oncogene was first developed, antibodies presented
themselves as an ideal targeting moiety. Antibodies are highly
specific towards a receptor, to which they display a high
affinity. While there are many types of antibodies, most anti-
bodies used for therapeutics are IgG antibodies. IgG antibodies
have a Y-shaped structure consisting of a constant (Fc) region
that is unchanged in all IgG antibodies and a variable (Fab)
region that is unique to each antibody (Fig. 2).
The development of antibodies as clinically approved thera-
peutics in their own right may have encouraged the development
of antibody-AuNPs. The antibodies trastuzumab and cetuximab
have been clinically approved to target HER2 overexpressing
breast cancers43 and EGFR overexpressing colorectal cancer
respectively.44 As these antibodies are clinically approved, their
affinity to their target has already been validated and therefore
they have both been extensively investigated for the targeted
Fig. 2 (L-R) the structures of an IgG antibody consisting of two heavy
chains (purple) and two light chains (pink) highlighting the Fab and Fc
regions, a camelid IgG heavy-chain antibody with variable recognition
domains (green) and a single-domain nanobody derived from the variable
domain of a camelid IgG.
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delivery of AuNPs. For example, cetuximab and trastuzumab
have been used to direct AuNPs towards cancers for enhanced
radiotherapy.45–48 AuNPs can act as radiosensitisers, increasing
the effect of radiation therapy on tumours as they release
photoelectrons and Auger electrons upon irradiation with
X-ray and near-IR radiation.49 Antibody-functionalised AuNPs
have also been extensively studied for targeted PTT of a multi-
tude of cancers.50–52 Consistently, increased cytotoxicity and
selective uptake of these targeted AuNPs is observed.
Antibody-functionalised AuNPs were first used for the
targeted delivery of anticancer agents in 2008, when gemcitabine
(Gem) was delivered to pancreatic adenocarcinoma by cetuximab-
functionalised AuNPs with increased cytotoxicity observed over
non-targeted Gem-AuNPs.53 Since then, AuNPs have been used to
deliver chemotherapeutic drugs such as doxorubicin (Dox),54,55
oxaliplatin56 and docetaxel.4 These chemotherapeutic drugs are
either bound to the AuNP core via reversible Au–N bonds,
adsorbed to the core through hydrophobic interactions or are
conjugated onto PEG ligands (Fig. 3) to form a mixed monolayer
on the nanoparticle surface alongside the antibody.54–56
Few examples exist of conjugating the delivered drug onto
the antibody itself,57 potentially due to the relative fragility of
antibodies and the relative ease of conjugating payloads to the
nanoparticle over the antibody. One example of this is the
addition of the radionuclide 131I to cetuximab post-conjugation
of this antibody onto AuNPs for radioimmunotherapy.58 The
decision to radiolabel the antibody itself likely stems from the
fact that radiolabelled cetuximab has been widely investigated
as an agent for radioimmunotherapy.59–61 These AuNPs were
seen to display a targeted decrease in cell viability of A549
cells, with this cytotoxicity higher than that of 131I at the same
dosage,58 highlighting the ability of AuNPs to increase the
potency of a payload.
The uptake of antibodies into cells often relies on receptor
mediated endocytosis. This process provides a target-specific
internalisation mechanism for antibody-AuNPs; however, the
conjugation of antibodies is notorious for altering the pharma-
cokinetics of the antibody. It has been observed that the
endocytosis of cetuximab-AuNPs is in fact accelerated from
that of free cetuximab, and the mechanism by which this
endocytosis occurs is altered upon conjugation. This altered
internalisation mechanism leads to differing subcellular
localisation between cetuximab and its resulting gold nano-
conjugate.62 It is also observed that not all antibodies are
internalised upon receptor binding. It is still under debate
whether trastuzumab is internalised upon binding to HER2,63,64
however it has been shown that the internalisation of
trastuzumab is increased upon cross-linking, possibly due to
multivalent binding. HER2 overexpressing cells show increased
internalisation of trastuzumab-AuNPs compared to non-
conjugated trastuzumab at the same concentration.65 These
reports highlight a key consideration for the synthesis of
antibody-AuNPs; the kinetics and uptake of the antibody is
likely to be altered upon conjugation. While in the reported
examples these alterations appear to be beneficial for increased
uptake, this may not always be the case and the pharmaco-
kinetics of conjugated antibodies may warrant further investi-
gation to help select the best antibodies possible for delivering
AuNPs to the corresponding target.
While many different antibody conjugated AuNP systems
have been reported, the vast majority of them rely on common
chemistry for the addition of the antibody to the nanoparticle
system. Firstly, most of these nanosystems are stabilised with a
thiolated linker such as a PEG chain, which is highly water
soluble and approved for medical use. These PEG chains are
often terminated with a carboxylic acid or activated succinimidyl
ester for the addition of an antibody through the formation of
random amide bonds with free amine residues on the surface
of the antibody.45–47,54–56,58,65–72 While many variants of these
linkers exist, the chemistry of the antibody conjugation is
identical. This ubiquity of functionalisation chemistry, while
concentrations of both coupling agents and antibody may need
to be varied depending on the desired system, perhaps high-
lights the versatility of antibodies as targeting agents for
AuNPs. It can be imagined that, if the same process is used
for antibody conjugation time and time again, antibodies can
be switched in and out to target the same system to any
oncogene required. While most conjugates in the literature
use some variation of this amide bond formation involving
lysines on the antibody, a PEG linker terminated in a hydrazide
can be used, which allows for the cross-linking of AuNPs with
carboxylic acids on the surface of antibodies.73 This chemistry,
while utilising different residues on the antibody is still
completely random and may lead to even more variations as
there are on average more carboxylic acids present on anti-
bodies than amines.74
While antibodies display high affinity towards their target,
this affinity relies on the antigen binding sites remaining non-
functionalised and unhindered. The commonly used random
amide bond formation for the addition of antibodies may result
in some of the amide bonds being formed in or near the active
site of the antibody, or orientating this active site towards
the gold core, and thus reducing the binding ability of these
conjugates. It has been shown that protein G, an Fc region
Fig. 3 Structure of antibody directed doxorubicin (blue) AuNPs, with both
the payload and antibody conjugated through a PEG (black) linker (adapted
from ref. 54).
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binding protein, can be used to control the orientation of an
antibody on the AuNP surface and therefore to maintain
optimal activity.75 While no comparison is made to AuNPs
conjugated with antibody without the presence of protein G,
there is increased uptake of these EGFR targeted AuNPs
compared to a non-targeted control and selective PTT is
observed.53,75 This perhaps provides a sensible alternative to
commonly used antibody functionalisation techniques if the
desired activity is not observed, however protein G is immuno-
genic and therefore it may provide other complexities.
2.2 Antibody fragments and nanobodies
While antibodies present such high affinity towards receptors,
their size may inhibit their penetration into tumours,76 and
it has been suggested that this effect is also observed for
antibody-conjugated AuNPs.77 The size-dependent penetration
issues have led to the investigation of antibody fragments as
targeting moieties. The reduction of the disulphide bonds
between the heavy chains of an antibody yields two functional
antibody fragments. Notable for AuNPs, these antibody frag-
ments possess free thiols which can bind to the gold core. This
conjugation strategy also ensures the active site of the antibody
is pointing away from the gold core and thus, is accessible. The
conjugation of EGFR antibody fragments to AuNPs for PTT
displayed cytotoxicity upon irradiation that varied with EGFR
expression.50 While the use of antibody fragments reduces the
size of the targeting moiety attached to the AuNPs, these half-
antibodies still display an immunogenic effect upon the body
due to the presence of the Fc region. Antibody fragments
known as Fab fragments have been developed to remove the
Fc region, simultaneously reducing the size of the antibody and
forming a non-immunogenic targeting moiety. Interestingly,
there are no examples of the use of Fab fragments to target
therapeutic AuNPs for cancer drug delivery, and research into
this area may provide exciting results.
While antibody fragments have been investigated to account
for the sheer size of antibodies, nanobodies are even smaller
than antibody fragments and have recently gained extensive
attention as targeting moieties.78 Camelids possess IgG anti-
bodies that consist of only heavy chains and are two thirds of
the size of human IgGs (Fig. 2).79 These camelid heavy-chain
antibodies possess a variable domain that can be cloned and
expressed in bacteria to give a monomeric, single-domain
antigen-binding antibody fragment, named a nanobody for its
small size (Fig. 2).79 Nanobodies are ca. 15 kDa, one tenth of the
size of an antibody, and therefore display higher tumour
penetration. Alongside this, they are non-immunogenic and
display higher stability than antibodies.80
An anti-HER2 nanobody has been shown to selectively target
AuNSs towards HER2 positive ovarian cancer. The nanobody
was shown to selectively internalise into HER2 overexpressing
SKOV3 cells, with targeted PTT observed.81 This nanobody was
modified in production to express a cysteine residue on the
C-terminus to allow for site-specific attachment onto AuNSs
through a maleimide. Both antibody fragments and nanobodies
may provide solutions to the issues of antibody penetration into
solid tumours. Further work is needed, however, to confirm the
benefit of these targeting moieties, with studies to compare the
uptake, selectivity and tumour penetration of these fragments to
that of whole antibodies to determine whether this effect is also
observed when conjugated to an AuNP core.
3. Protein directed gold nanoparticles
The use of native proteins as targeting agents is relatively
unexplored compared to the wealth of research into antibody
targeted therapies. Proteins selected as targeting moieties are
either natural ligands for a receptor or lectins – carbohydrate
binding proteins often isolated from fruit or vegetables. It is
perhaps understandable that human native protein ligands
towards receptors have not been extensively explored as targeting
moieties as, by nature of their abundance in the human body,
there will be a large number of competing ligands that are not
carrying AuNPs. These proteins will display the same affinity
towards the desired receptor and possibly lead to a reduced
targeting efficiency. That said, the use of human proteins and
growth factors removes any immunogenic response towards these
AuNPs and may be worth exploring. One growth factor that has
been exploited for targeted AuNP therapy is the epidermal growth
factor (EGF) which has been used to target AuNPs towards
epidermal growth factor receptor (EGFR) overexpressing breast
cancer. A disulphide bond in EGF was reduced to allow for its
attachment onto AuNPs, then the EGF itself was radiolabelled
with 111In (Fig. 4). These nanoconjugates showed high uptake into
EGFR overexpressing breast cancer cells and minimal uptake into
cells with low EGFR expression. A competition assay with non-
conjugated EGF showed that this uptake was due to EGF recogni-
tion by the cells and EGFR selective cytotoxicity was observed.82
The protein transferrin has been shown to target AuNRs
towards transferrin receptor expressing lung cancers. While
transferrin directed AuNRs carrying doxorubicin displayed
lower cytotoxicity than doxorubicin alone, the cytotoxicity of
these transferrin targeted AuNRs was selective towards trans-
ferrin receptor expressing cells, and toxicity was shown to vary
with the concentration of transferrin receptor expressed by cell
lines.83
While these examples use the receptors’ native proteins, the use
of recombinant proteins has been explored. Employing mutations
Fig. 4 The functionalisation of AuNPs with 111In radiolabelled EGF
through disulphide reduction.82
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and variations to wild type proteins for a ligand can advantageously
alter their characteristics and lead to enhanced properties for
these recombinant proteins over the body’s native proteins. For
example, a recombinant fibroblast growth factor 1 (FGF1) was
engineered with four point mutations to protect FGF1 against
proteolysis and therefore increase its circulatory half-life over
that of native FGF1.84 FGF1 targets all four variations of the
fibroblast growth factor receptor that are overexpressed in many
cancers including lung cancer.85 FGF1 was also altered to attach
a short peptide chain to the N-terminus containing a cysteine for
conjugation onto AuNPs, and the native cysteine in the protein
was removed to allow for site specific conjugation onto the
AuNPs. FGFR negative cells were transfected with FGFR and
the uptake of these nanocarriers confirmed to be due to endo-
cytosis by FGFR. These AuNPs were used for PTT, with photo-
thermal cytotoxicity only observed in FGFR expressing cell
lines.86 The benefits of this recombinant protein over native
FGF1, however, have not been explored in this research as no
comparison has been made to the native ligand to determine the
advantage of this increased circulatory half-life.
Lectins are more commonly used for biosensors than for
targeted cancer therapies, however the lectin Jacalin has been
employed to target a zinc phthalocyanine towards Thomsen–
Friedenreich antigen (T-antigen) expressing cells for photo-
dynamic therapy (PDT). The T-antigen is expressed in ca. 90%
of cancers and is usually cryptic on healthy cells. Jacalin was
conjugated onto a PEG shell through random amide-bond
formation and cytotoxicity was observed in T-antigen expres-
sing cells, whereas non-conjugated AuNPs displayed negligible
cytotoxicity. Pre-incubation with Jacalin binding glycoproteins
reduced the phototoxicity, confirming the observed activity
was due to the selectivity of Jacalin.67,87 Jacalin is non-
immunogenic, and its affinity towards the ubiquitously onco-
logically expressed T-antigen makes it an exciting targeting
moiety. Jacalin has, however, been shown to bind to carbo-
hydrate moieties on IgA antibodies,88,89 which may limit its use
as a targeting ligand.
4. Peptide directed gold nanoparticles
Peptides are relatively short polymers of amino acids that can
be fully characterised and chemically synthesised to a designed
specification. While they generally display lower affinity towards
receptors than antibodies and other proteins, peptides are
gaining attention as targeting moieties due to their simplicity
and rapid uptake kinetics. Many examples of using peptides to
target AuNPs towards various cancers for imaging have been
reported in the literature,90–95 while surprisingly few examples
exist of peptide-directed AuNP-based cancer therapeutics.
Peptides have been used to direct AuNPs carrying cytotoxic
payloads to their targets. Pancreatic ductal adenocarcinoma
(PDAC) has been targeted using a plectin-1 targeting peptide
(KTLLPTP). Plectin-1 is expressed on the surface of PDAC but
only within the cytoplasm of healthy cells.96 The modification
of this peptide with a tyrosine and a cysteine residue
(KTLLPTPYC) allows for the use of this peptide to simulta-
neously reduce gold(III) chloride under basic conditions to
initiate the nucleation of AuNPs (Tyr), and to cap the resulting
nanoparticles with the thiol side chain of cysteine. This addition
of a dipeptide that simultaneously nucleates and caps AuNPs is a
unique modality for peptides over all other targeting agents.
These AuNPs were further functionalised with the chemo-
therapeutic drug gemcitabine (Gem), which adsorbs to the AuNP
core through hydrophobic interactions, as well as forming a
reversible Au–N bond.97 These AuNPs show higher cytotoxicity
towards PDAC cell lines than Gem alone and display excellent
selectivity for PDAC cells over healthy tissue in mouse models.97
This use of the YC dipeptide to simultaneously nucleate and
cap AuNPs has also been used to form AuNPs for use as radio-
sensitisers. These AuNPs are targeted towards avb3 integrin
expressing cells through the cyclic peptide c(RGD) (Fig. 5).98
Arg-Gly-Asp (RGD), and its cyclic derivative c(RGD), can be
used to direct AuNPs to a wide variety of cancers as avb3
integrin is expressed by proliferating endothelial cells involved
in angiogenesis.99 The enhanced rate of angiogenesis in can-
cerous tissues means there is a high expression of avb3 integrin
in most endothelial cancers. RGD is possibly the most well-
known targeting peptide and this tripeptide highlights the
ability to produce very small targeting peptides towards receptors
while maintaining selectivity. Both RGD and cRGD have been
shown to selectively direct AuNPs towards breast cancers
and glioblastomas, where these AuNPs can act as radio-
sensitisers.100,101 c(RGD) has been used to deliver siRNA to
cervical cancer models to silence E6, an oncoprotein that
inactivates p53.102 The cRGD peptide is conjugated to a PEG-
poly-lysine block copolymer, which is utilised to bind the siRNA
through steric repulsion and ionic parings. Here, the ligand itself
acts as the drug carrier and increased siRNA is observed intra-
cellularly for cells treated with cRGD functionalised siRNA-AuNPs
Fig. 5 The synthesis of cRGD directed AuNPs using a YC dipeptide (blue) to nucleate and cap the AuNPs (adapted from ref. 98).
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over cRAD functionalised siRNA-AuNPs; a substituted peptide
sequence used as a control. The targeting ability of cRGD was
further confirmed by pre-incubating cells with cRGD before the
addition of cRGD-siRNA-AuNPs, with a much lower siRNA uptake
observed.103
The peptide CRGDK is specific towards neuropilin-1 (Nrp-1),
a transmembrane glycoprotein that acts as a co-receptor for
many ligands and regulates the internalisation of membrane
receptors. CRGDK has been used to direct AuNPs carrying the
therapeutic peptide p12 (TSFAEYWNLLSP) towards Nrp-1
expressing breast cancers,104 and CRGDK-AuNPs carrying a
platinum(IV) agent have been directed towards prostate
cancers.105 p12 inhibits the binding of MDM2/MDMX to
p53, a tumour suppressor, but it cannot penetrate the cell
membrane, while Pt(IV) acts as a chemotherapeutic. Increased
cytotoxicity was observed with increased Nrp-1 expression, and
pre-treatment of cells with an Nrp-1 antibody resulted in
reduced uptake of these nanoparticles, confirming the CRGDK
peptide is targeting these AuNPs towards Nrp-1 overexpressing
cells,104,105 highlighting the ability of short peptide sequences
to selectively target an oncogenic receptor.
The EGFR targeting peptide GE11 (YHWYGYTPQNVI) has
been used to deliver AuNPs carrying the photosensitiser Pc4 to
EGFR overexpressing glioblastoma cells.106,107 PEG-AuNPs were
synthesised and conjugated with GE11 before Pc4 was adsorbed
onto the surface of the AuNP. These nanoconjugates displayed
minimal dark toxicity and significant phototoxicity in glioblas-
toma cells. Interestingly, it was found that few nanoparticles were
accumulating within the cells, however the concentration of Pc4
internalised by these cells was seen to be dependent on the
binding of GE11. Pre-incubation of the cells with GE11 reduced
uptake of Pc4 into these glioblastoma cells, and therefore it was
hypothesised that while the AuNPs themselves were not being
internalised, it is thought that the increased interaction of these
directed AuNPs with the surface of glioblastoma cells allows for
the Pc4 to desorb from the nanoparticle and accumulate within
glioblastoma cells.106,107 As these nanoparticles are designed to
pass through the blood brain barrier (BBB), it is vital that their
size is maintained as small as possible. The relatively small size of
peptides over antibodies and other proteins is beneficial here, and
GE11 shows an affinity for the EGFR receptor only 10-fold lower
than that of its natural ligand EGF, highlighting the applicability
of peptides as targeting agents. The small size and fully charac-
terised structure of peptides provides a benefit over antibodies
and other proteins. The relative stability of peptides over anti-
bodies and other proteins means they can either be conjugated to
linkers after their attachment to AuNPs or before their use for
ligand exchange. Again, as with antibodies and other proteins, the
use of EDC/NHS and their derivatives is popular for peptide
conjugation.104–107 As peptides are synthetically produced, their
structures can be easily modified for attachment of reactive
moieties. This allows for the attachment of thiols through cysteine
residues that have been used to conjugate peptides directly to the
gold core or to conjugate a peptide onto a linker.100,101,108 Most
notably, the use of peptides allows site specific conjugation of the
targeting moiety to AuNPs. This ensures that the peptides are
attached to the AuNPs in a way that maintains their binding
capability towards their target.
5. Aptamer directed gold
nanoparticles
Aptamers are short, single stranded DNA or RNA sequences
selected from a random pool of oligonucleotides. They form
secondary structures through complementary base pairings
that allow for selective binding towards specific receptors,
proteins and small molecules (Fig. 6), with an affinity for their
target similar to that of an antibody.109–111
Aptamers can be chemically synthesised and easily modified
to improve their pharmacokinetics and stability, and therefore,
since their development in the 1990s, have been viewed as an
exciting alternative to antibodies.112 The synthetic production
of aptamers means that most reports of aptamer-functionalised
AuNPs use thiolated aptamers for direct attachment to the gold
core,113–118 however one example does exist of amide bond
formation to a PEG shell.119
Numerous aptamers have been designed for various targets,
however only a select few of these have been applied to the
delivery of AuNPs. The most widely explored aptamer for AuNP
targeting is AS1411 – a 26-base guanine rich aptamer that
targets nucleolin, a phosphoprotein overexpressed by cancer-
ous cells.120 Nucleolin is mainly expressed on the nucleus of
healthy cells, but malignant mutation often leads to increased
localisation of this receptor onto the surface of cancerous
cells.120 The guanine rich sequence of AS1411 leads to the
formation of a G-quadruplex structure that is selective towards
nucleolin. AS1411 induces an anti-proliferative effect within
cells itself, and this in combination with its targeting ability
increases the efficacy of a therapy. AS1411 has been used for
the delivery of AuNPs for PTT,119 radiotherapy121 and to deliver
AuNPs carrying Dox with nucleolin selective cell death
observed.113 As AS1411 forms a G-quadruplex in the presence
of potassium, the aptamer can be used to bind the photosensi-
tiser N-methylmesoporphyrin IX (NMM), a G-quadruplex DNA
binding ligand. The thiolation of this aptamer allows for its
direct addition to the surface of AuNPs and these nanoconju-
gates were seen to be selectively internalised by cancer cells
overexpressing nucleolin, with no uptake observed in nucleolin
Fig. 6 Aptamers as targeting moieties: the folding of aptamers through
complementary base pairings results in secondary structures that are
highly specific towards target receptors (adapted from ref. 111).
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negative normal cell lines.114 This example is particularly inter-
esting as it utilises the aptamer sequence not only as a targeting
moiety but also as a drug carrier. A second example of this
involves the conjugation of the photosensitiser chlorin e6
(Ce6) to the aptamer sgc8c, a protein tyrosine kinase 7 (PTK7)
selective aptamer, to selectively target it towards leukaemia cell
lines. Ce6 is conjugated to the 30-end of the sgc8c aptamer,
which is conjugated to a poly-T chain at the 50-end, which, in
turn, is conjugated to a sgc8c complementary DNA (cDNA)
sequence. The sgc8c cDNA is further conjugated to AuNRs
(Fig. 7). This means that in the absence of PTK7, the sgc8c is
hybridised with the cDNA sequence, holding Ce6 close to the
AuNR and quenching its fluorescence. Upon binding to PTK7,
the sgc8c forms a hairpin, losing affinity for its complementary
sequence and moving the Ce6 away from the AuNR, ‘switching
on’ its fluorescence and therefore its photodynamic activity, as
shown in Fig. 7. Significant targeted photodynamic activity was
observed in PTK7 expressing cells, with increased cytotoxicity
observed in combination with PTT.115
As aptamers are oligonucleotides, chemotherapeutic drugs
that act by intercalating DNA can also intercalate these
aptamers. Dox is a reversible DNA intercalator and therefore
can be delivered to its target by binding to aptamers, notably by
sgc8c and A9, a prostate specific membrane antigen (PSMA)
specific aptamer.116,117 Here, AuNPs act as delivery systems to
increase the concentration of payload delivered – multiple
drug-aptamer complexes can be delivered at once, increasing
the potency of one ligand finding its target. This effect has
also been observed with the HER2 aptamer HApt; a trimeric
aptamer that displays cytotoxicity towards HER2 overexpressing
breast cancers by cross-linking HER2 receptors and sorting
them for degradation. The attachment of this aptamer onto
AuNSs has been shown to increase its uptake and therefore the
therapeutic value of HApt.118
Aptamers, while successful targeting moieties when used
individually, have also been used in combination to target
multiple receptors on a specific cancer and therefore increase
the selectivity towards these cells. AS1411 has been utilised for
targeting AuNPs in conjunction with sgc8c, highlighting one of
the advantages of aptamers as targeting moieties. As aptamers
can be synthetically designed and built to a desired specification,
a polyvalent aptamer system can be designed containing both
AS1411 and sgc8c.122 The formation of a polyvalent aptamer for
dual targeting displays remarkable benefits over the attachment
of two individual targeting moieties as the ratio of these targeting
ligands can be completely controlled with no concerns that one
aptamer may have a higher affinity for AuNPs than another. It can
be envisaged that ligands bearing multiple aptamers, or an
uneven ratio of two aptamers could be synthesised to further
increase the number of receptors targeted or alter the ratio of the
targeting ligands in a controlled manner. This polyvalent aptamer
was attached to AuNPs through electrostatic interactions, followed
by the addition of daunorubicin (Dau), a DNA intercalating
chemotherapeutic. A small amount of Dau binds to the aptamer
due to its DNA intercalating ability, but the majority is bound to
the AuNP surface through electrostatic interactions. These AuNPs
displayed selective cytotoxicity towards cancer cell lines expressing
both nucleolin and PKT7. A synergistic effect was observed for the
use of this polyvalent aptamer over AuNPs targeted with just
the sgc8c aptamer,122 highlighting a benefit of these chemically
synthesised targeting moieties.
6. Carbohydrate directed gold
nanoparticles
Cancer cells have been found to differentially express lectins on
their surface compared to healthy cells,123 and the affinity of
carbohydrates towards these lectins can be exploited to target
these cells.124 The use of carbohydrates as targeting moieties
for AuNP-based therapeutics is a relatively new concept, with
literature exploring this possibility only disclosed within the
last six years. As this is such a new field, few carbohydrate
ligands have been explored.
Hyaluronic acid (HA, Fig. 8a) is a naturally occurring poly-
saccharide consisting of a repeating unit of D-glucuronic acid
and N-acetyl-D-glucosamine. HA selectively targets the CD44
receptor which is overexpressed by various cancers with a
kD E 0.3 nM.
125 The polymeric structure of HA means that
there are multiple free carboxylic acids that can be used for
drug functionalisation and this has been exploited for the
delivery of chemotherapeutic drugs and photosensitisers to
their targets.126 A porphyrin photosensitiser has been conju-
gated onto HA alongside the fluorescent imaging agent cresyl
violet and cystamine, which adds a thiol functional group for
conjugation of this linker onto AuNPs (Fig. 8b). Here, HA acts
as both the linker and targeting moiety. When attached to
AuNPs, the fluorescence of both the porphyrin and cresyl violet
are quenched. Upon uptake by CD44 overexpressing cell lines,
hyaluronidase enzymes can degrade the HA, releasing the
attached fluorophores and allowing for both the imaging of
CD44 overexpressing cancers and their targeted PDT. The
uptake and cytotoxicity of these nanoconjugates was observed
Fig. 7 Activatable Ce6 AuNR targeted towards leukaemia cells through
sgc8c aptamer (adapted from ref. 115).
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to be selective towards CD44 overexpressing cancer cell lines.126
The highly repeated sequence of the HA polysaccharide allows
HA to act as both a linker and targeting moiety, as well as
allowing for functionalisation with a variety of drugs without the
loss of targeting ability, a unique property of these polysaccharide
targeting moieties. The photosensitiser pheophorbide-A and the
chemotherapeutic drug metformin have both been conjugated
onto HA with selective uptake observed in CD44 overexpressing
lung and liver cancers, respectively.127,128
While HA is sparsely described in the literature as a targeting
agent for therapeutic AuNPs, it is by far the most investigated
carbohydrate ligand. One of the few examples of alternative
carbohydrate ligands is that of glucose, a monosaccharide that
has been shown to bind to glucose transporter-1 (GLUT1) which
is overexpressed by several cancer cells. Glucose functionalised
AuNPs have been used to target siRNA carrying AuNPs towards
GLUT1 overexpressing breast cancers.129 As glucose is a mono-
saccharide, the technique of conjugating drugs directly to the
carbohydrate as used for HA cannot be utilised. Instead, this
work builds a glucose-capped ligand containing a PEG chain,
followed by a 40-unit poly-lysine (PLL) chain, and terminated in
lipoic acid (Fig. 9). The PEG chain acts as a spacer and provides
water dispersibility, while the lipoic acid provides thiols for
binding to the AuNP surface. The PLL chain acts to bind siRNA
through electrostatic interactions as the PLK1 siRNA used in this
study contains 40 negative charges. PLK1 plays a vital role in the
cell cycle of cancer cells and its knockdown leads to antitumour
activity. This system was observed to specifically target GLUT1
overexpressing breast cancer cells, with its specificity confirmed
through a competition assay with the GLUT1 inhibitor
phloretin.129
Lactose, a disaccharide that is recognised by the lectin
galectin-1, has also been investigated as a targeting moiety
for AuNP-based cancer therapeutics.130 It has been used to
target AuNPs carrying a phthalocyanine photosensitiser
towards breast cancer cells for PDT. Lactose was conjugated
onto a short, thiolated PEG linker and functionalised onto
the gold core in a mixed monolayer with the photosensitiser.
While uptake and phototoxicity was specific towards malignant
breast cells, the uptake was not determined by the presence of
galectin-1.130 This work, while demonstrating the possibility of
the use of carbohydrate based ligands as targeting moieties,
requires additional studies to determine how this ligand is
selectively targeting malignant cells.
7. Small molecule directed gold
nanoparticles
The final class of targeting moieties explored for AuNPs is small
molecules; low molecular weight organic compounds that
display affinity towards cell surface receptors. Benefits of small
molecules include the fact that they can be relatively cheap to
synthesise and generally display higher stability than the other
targeting moieties discussed above. Due to their size, small
molecules easily penetrate through tumours to deliver payloads
to their target. Folic acid, also known as folate, is the most
commonly utilised small molecule for targeted AuNPs. It is a
natural ligand towards the folate receptors, which are only
accessible to the blood stream in the kidneys on cancerous
cells and therefore are useful oncogenic targets.131 The struc-
ture of folic acid contains two carboxylic acids which can be
used for conjugation onto AuNPs. Due to the small size of folic
acid, it is not possible to use this ligand to carry the payload
and to conjugate it onto the AuNP itself. Folate is most
commonly conjugated onto a linker such as PEG or polyethyl-
enimine (PEI, Fig. 10) through amide bonds for attachment
onto AuNPs, but examples of using electrostatic interactions
to bind folate to AuNPs do exist.132 Covalently bound folic acid
has been used to deliver AuNPs carrying siRNA, photosensitisers
and chemotherapeutic drugs to various cancers.133–135 The use of
folic acid-AuNPs to deliver chemotherapeutics often relies on
electrostatic interactions between the drug, such as Dox, and the
surrounding ligands, such as pectin.136 The release of Dox from
these AuNPs has been shown to increase at lower pH due to the
protonation of the negatively charged pectin shell and therefore a
loss of the electrostatic interaction. The pH of tumour cells is
pH 5.4, compared to 7.4 of the bloodstream, so this is a favour-
able characteristic for drug release in the tumour site. While in
this case the AuNPs act solely as a delivery system, an increased
cytotoxicity is observed for AuNP bound Dox compared to that
of free Dox.136 As well as increasing the potency of chemo-
therapeutic effects, AuNPs allow for combination therapies
between chemotherapeutics and PTT, with the synergistic effect
Fig. 8 (a) the repeating D-glucuronic acid and N-acetyl-D-glucosamine
unit of HA and (b) substituted HA ligand for AuNPs for the dual imaging and
PDT of CD44 overexpressing cancer cells.126
Fig. 9 The attachment of glucose (blue) onto AuNPs through a PEG
(green), PLL (pink) and lipoic acid (black) chain.129
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resulting in increased cytotoxicity, and the folate ligand provid-
ing selectivity towards folate receptor positive tumours.135,137
Interestingly, for the development of folate-targeted AuNP
therapies, there are examples that display increased cytotoxicity
upon the addition of folic acid,134,136 however no control folate
receptor negative cell line or competition assay is run to prove
that this increase in cytotoxicity is indeed receptor mediated
and selective towards folate receptor overexpressing cancers.
To assess the true benefits of folate-targeting AuNPs it is vital
that the selectivity of these nanoconjugates is fully assessed, as
this increase in cytotoxicity may be due to increased passive
penetration and therefore these approaches may not provide
any gain over non-targeted AuNPs.
While most examples of small molecule targeted AuNP
therapies use folate as their targeting moiety, examples exist
using other small molecules. Anisamide is known to bind to the
Sigma receptor which is overexpressed in prostate cancer and
has been used to deliver AuNPs carrying siRNA to their target.
Anisamide is a synthetically produced small molecule derived
from anisole, a naturally occurring molecule found in aniseed
oil.138 The use of anisamide highlights another advantage of
small molecules – they can be easily modified through structure–
activity relationship studies to optimise their binding towards a
target and remove unnecessary complexities from molecules
that are not involved in the binding to a receptor. As with folic
acid, anisamide lacks conjugation sites, meaning the siRNA is
attached through electrostatic interactions with a PEI coating
on the gold core (Fig. 11). The anisamide itself is synthesised by
conjugating anisic acid to PEI ligands on these nanoparticles.
For siRNA delivery, non-covalent attachment appears to be
the most efficient delivery system as the siRNA can diffuse
away upon internalisation by cancerous cells where the pH
is decreased, and the PEI becomes deprotonated. Anisimide-
AuNPs-siRNA are shown to trigger apoptosis due to mRNA
knockdown, with this cytotoxicity observed to be receptor
mediated.139,140
a- and b-bicalutamide are antiandrogens, small molecules
known to bind the androgen-sensing G protein coupled recep-
tor GPRC6A and the membrane androgen receptor (MAR), both
expressed by prostate cancers. These antiandrogens are cur-
rently clinically used for chemotherapy of prostate cancer, but
their attachment onto PEGylated AuNPs (Fig. 12) has shown
selective cytotoxicity in MAR/GPRC6A positive chemo-resistant
prostate cells.141 In the work reported, the use of a selective
chemotherapeutic drug as the targeting moiety for AuNP
delivery displays the benefits of AuNPs as delivery vehicles.
This ability of AuNP conjugation to increase the uptake of
already selective chemotherapeutic drugs through multivalent
binding is an exciting prospect.
8. Gold nanoparticles with multiple
targeting modalities
The multivalency of AuNPs provides the opportunity to func-
tionalise the surface with multiple directing moieties to target
multiple receptors, and these targeting moieties do not have to
be of the same class. Gold nanostars have been functionalised
with a mixed monolayer of the aptamer A10 and the peptide
DUP-1.142 A10 is PSMA specific and DUP-1 binds to an
unknown site on prostate carcinomas. It was found that the
combination of these targeting modalities allowed for selective
targeted PTT of prostate cancers, regardless of their PSMA
expression.142
AuNPs carrying the ribosome inactivating protein curcin
have been targeted towards glioblastoma using a combination
of folic acid and an anti-transferrin antibody.143 Glioblastomas
overexpress both the FRa and the transferrin receptors.
Increased uptake was observed for the dual targeted AuNPs
compared to AuNPs functionalised with just folic acid, high-
lighting the benefit of dually targeting these nanocarriers.
Selective cytotoxicity was observed in glioblastoma cells, and
the use of curcin was seen to display a synergistic cytotoxicity
when delivered by AuNPs that were subsequently used for PTT.143
Fig. 10 The conjugation of folic acid (blue) onto PEI (black) functionalised
AuNPs.
Fig. 11 Anisamide (blue) conjugated onto AuNPs through PEI (black), with
the siRNA payload (green) electrostatically coordinated to the PEI.139,140
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These examples highlight the benefits of targeting multiple
receptors to either widen the therapeutic value of an AuNP
system to a higher percentage of a certain cancer type, or to
use the synergistic targeting abilities of two moieties to
increase specificity towards a target. Most importantly here,
these results show that these targeting modalities can be
mixed and matched to enhance the targeting ability of AuNPs
without interfering with each other, allowing for a large variety
in targeting combinations to establish the best possible treatment
for specific cancers.
9. Conclusions and future prospects
AuNPs present themselves as ideal drug carriers due to their
biocompatibility, facile functionalisation with various ligands,
their easily tuned size and shape and their enhanced absorp-
tion characteristics due to their surface plasmon absorption
band. While AuNPs display passive targeting towards tumours
through the EPR effect, with the current trend in developing
personalised medicines, the active targeting of AuNPs towards
tumours is growing in popularity. Oncogenes expressed on the
surface of cancer cells can be directly targeted by antibodies,
Fig. 12 Structures of (a) a-bicalutamide (blue) and (b) b-bicalutamide (pink) AuNPs, conjugated through a PEG linker (black).141
Table 1 Summary of cellular targets exploited for actively targeted AuNP therapies, the class of targeting moiety and the type of cancer treated
Receptor Targeting moiety Cancer type
EGFR Antibody Head and neck,47,60 breast,48,70 bladder,50 pancreatic,53,58 skin59
Protein Breast82
Peptide Glioblastoma106,107
HER2 Antibody Breast,45,46,48,57,67,68,72,75 gastric73
Nanobody Ovarian81
Aptamer Breast118






Carbohydrate Glioblastoma,126 lung,127 liver128
Transferrin receptor Protein Lung83
Antibody Glioblastoma143
FGFR Protein Lung84
T antigen Protein Colon67,87
Plectin-1 Peptide Pancreatic97
avb3 integrin Peptide Cervical,
98,103 breast,100 glioblastoma101
Neuropilin-1 Peptide Breast,104 prostate105
Nucleolin Aptamer Melanoma,113 breast,119,121 cervical114
PSMA Aptamer Prostate117,142
PTK7 Aptamer Leukaemia115,116,122
Glucose transporter-1 Carbohydrate Breast129
Galectin-1 Carbohydrate Breast130
Folate receptor Small molecule Bile duct,132 cervical,134 breast,135,137 colon,136 glioblastoma143
Sigma receptor Small molecule Prostate139,140
GPRC6A/MAR Small molecule Prostate141
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proteins, peptides, aptamers, carbohydrates and small molecules,
and their attachment onto AuNPs leads to selective uptake
through receptor mediated endocytosis. The receptors and
types of targeting moieties exploited for actively targeting
AuNPs to cancers are summarised in Table 1.
Antibodies are most commonly conjugated onto AuNPs
through water soluble ligands, with the payload conjugated
to the core instead of to the antibody itself. Antibodies are
perhaps the most widely investigated targeting moiety to func-
tionalise AuNPs due to their extremely high selectivity and
affinity towards their target receptors. The use of antibodies
is, however, more expensive than the majority of other targeting
moieties and antibodies display low tumour penetration due to
their large size. Antibody fragments and nanobodies are now
widely investigated to combat this low penetration, however
this decrease in size reduces the circulatory lifetime.
Aptamers display receptor affinity close to that of an anti-
body and therefore potentially provide a good alternative to
antibodies. Aptamers display higher stability than antibodies
towards organic solvents and pH which is ideal for the synth-
esis of nanocarriers. Aptamers are also chemically synthesised
which allows for easier modification and characterisation than
antibodies, and payloads can be directly attached to these
targeting moieties. These synthetic targeting moieties allow
for the synthesis of ligands bearing multiple targeting moieties,
which could allow for the targeting of multiple receptors with
one nanocarrier. Aptamers can themselves elicit anti-tumour
effects, and therefore can act as both a targeting moiety and
a drug. Payloads can also be directly attached to aptamers
without effecting their affinity to a receptor, providing an
alternative method for payload delivery on AuNPs as they do
not have to be directly bound to the gold core. While these
benefits highlight aptamers as a beneficial targeting moiety,
they display low stability in circulation due to nucleases in
blood plasma.144 Due to the inherent negative charge of aptamers,
they cannot be developed to target receptors that display
negatively charged surfaces, providing severe limitations to these
targeting moieties.
Protein ligands are also investigated as targeting moieties,
displaying a high affinity towards their target. The synthesis
of therapeutic protein-AuNPs usually involves the protein and
payload separately conjugated to the core through linkers.
Their affinity towards receptors is generally lower than that of
antibodies and aptamers and their relative abundance in the
body perhaps reduces their efficacy as there is a lot of natural
competition for a binding site.
The low penetration of antibodies and other proteins into
tumours has led to the investigation of peptides as targeting
moieties. While peptides generally show a lower affinity towards
the target receptor, the small size of peptides means they can be
synthesised, which allows for ease of modification and control
over the binding of these peptides onto nanocarriers. This allows
for site-specific conjugation of peptides onto AuNPs and ensures
that the amino acids vital for receptor binding remain exposed,
a benefit over antibodies and proteins where the conjugation onto
AuNPs can be completely random and these binding sites could
be blocked. Peptides are also more stable towards pH and organic
solvents than proteins, which increases the ease of synthesis of
peptide targeted nanocarriers. While their uptake and versati-
lity is high, peptides display a low circulatory half-life due to
peptidases in blood plasma,145 and their half-life is similar to
that of aptamers.
The expression of lectins on the surface of cancerous
tissue has recently led to the investigation of carbohydrates
as targeting moieties for AuNPs. Carbohydrate ligands are
either attached directly to the gold core or conjugated through
linkers. Carbohydrates display high affinities towards their
targets and, while their synthesis may be more complicated,
they can be modified to fit the desired purpose prior
to attachment onto a nanocarrier system. Highly polymeric
carbohydrates such as hyaluronic acid allow for the attachment
of payloads onto the targeting ligand itself and, as with
aptamers, this provides an interesting alternative to directly
binding a payload to the gold core, which may display signifi-
cant advantages for some payloads. The relative lack of inves-
tigation into these targeting moieties means that it is hard to
conclude on the impact these ligands may have, however some
carbohydrates display affinity towards multiple receptors,146
and this may decrease the efficacy of carbohydrate directed
therapeutics and lead to off-target effects.
Small molecules are low molecular weight organic com-
pounds that display increased circulatory stability over other
targeting moieties as they are not degraded by peptidases
or nucleases found in the blood stream. Due to the size of
small molecules, they have limited conjugation sites, so both
the small molecules and payloads tend to be conjugated onto
AuNPs through linkers. The size of small molecules means
that they generally display high tumour penetration, and small
molecules can themselves elicit a therapeutic effect upon
internalisation. Small molecules, however, generally display a
lower affinity and selectivity towards their target than anti-
bodies, proteins and aptamers.
The active targeting of AuNPs has allowed for the develop-
ment of previously unknown cancer therapies with exciting
potential. While each of the targeting modalities presented
in this review display their own unique characteristics and
advantages, there is little work comparing the ability of these
modalities to deliver AuNPs. This lack of comparison makes
it difficult to conclude whether the benefits of one targeting
moiety outweighs the disadvantages of another, and to
continue to push this field forward, comparisons between
different targeting modalities for the same receptor are needed
to determine the most effective approach. These comparisons
could allow for the development of highly potent ‘magic bullets’
for the treatment of cancers, with the specificity observed for
actively targeted nanoconjugates showing that AuNPs have a
bright future in cancer therapeutics.
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27 M. Grzelczak, J. Pérez-Juste, P. Mulvaney and L. M. Liz-
Marzán, Chem. Soc. Rev., 2008, 37, 1783.
28 C. Daruich De Souza, B. Ribeiro Nogueira and M. E. C. M.
Rostelato, J. Alloys Compd., 2019, 798, 714–740.
29 P. Zhao, N. Li and D. Astruc, Coord. Chem. Rev., 2013, 257,
638–665.
30 L. M. Liz-Marzán, Chem. Commun., 2013, 49, 16–18.
31 R. Herizchi, E. Abbasi, M. Milani and A. Akbarzadeh, Artif.
Cells, Nanomed., Biotechnol., 2016, 44, 596–602.
32 L. Freitas De Freitas, G. Henrique Costa Varca, J. Gabriel,
S. Batista and A. B. Lugão, Nanomaterials, 2018, 8, 939.
33 M. J. Hostetler, J. E. Wingate, C.-J. Zhong, J. E. Harris,
R. W. Vachet, M. R. Clark, J. D. Londono, S. J. Green,
J. J. Stokes, G. D. Wignall, G. L. Glish, M. D. Porter,
N. D. Evans and R. W. Murray, Langmuir, 1998, 14, 17–30.
34 X. Ma, Y. Wu, S. Jin, Y. Tian, X. Zhang, Y. Zhao, L. Yu and
X.-J. Liang, ACS Nano, 2011, 5, 8629–8639.
35 B. D. Chithrani, A. A. Ghazani and W. C. W. Chan, Nano
Lett., 2006, 6, 662–668.
36 Z. Lin, N. A. Monteiro-Riviere and J. E. Riviere, Wiley
Interdiscip. Rev.: Nanomed. Nanobiotechnol., 2015, 7, 189–217.
37 S. Eustis and M. A. El-Sayed, Chem. Soc. Rev., 2006, 35, 209–217.
38 X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed,
Lasers Med. Sci., 2008, 23, 217–228.
39 Y. J. Gu, J. Cheng, C. W. Y. Man, W. T. Wong and
S. H. Cheng, Nanomedicine, 2012, 8, 204–211.
40 S. D. Brown, P. Nativo, J. A. Smith, D. Stirling, P. R.
Edwards, B. Venugopal, D. J. Flint, J. A. Plumb, D. Graham
and N. J. Wheate, J. Am. Chem. Soc., 2010, 132, 4678–4684.
41 S. Ruan, X. Cao, X. Cun, G. Hu, Y. Zhou, Y. Zhang, L. Lu,
Q. He and H. Gao, Biomaterials, 2015, 60, 100–110.
42 M. Camerin, M. Moreno, M. J. Marı́n, C. L. Schofield,
I. Chambrier, M. J. Cook, O. Coppellotti, G. Jori and
D. A. Russell, Photochem. Photobiol. Sci., 2016, 15, 618–625.
43 K. Mckeage and C. M. Perry, Drugs, 2001, 1, 209–243.
44 D. J. Jonker, C. J. O’Callaghan, C. S. Karapetis, J. R.
Zalcberg, D. Tu, H.-J. Au, S. R. Berry, M. Krahn, T. Price, R. J.
Simes, N. C. Tebbutt, G. van Hazel, R. Wierzbicki, C. Langer
and M. J. Moore, N. Engl. J. Med., 2007, 357, 2040–2048.
45 N. Chattopadhyay, Z. Cai, Y. L. Kwon, E. Lechtman, J.-P.
Pignol and R. M. Reilly, Breast Cancer Res. Treat., 2013, 137,
81–91.
46 N. Chattopadhyay, Z. Cai, J. P. Pignol, B. Keller,
E. Lechtman, R. Bendayan and R. M. Reilly, Mol. Pharma-
ceutics, 2010, 7, 2194–2206.
47 A. Popovtzer, A. Mizrachi, M. Motiei, D. Bragilovski,
L. Lubimov, M. Levi, O. Hilly, I. Ben-Aharon and
R. Popovtzer, Nanoscale, 2016, 8, 2678–2685.


































































































Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2020
48 S. Yook, Z. Cai, J. J. Jeong, Y. Lu, M. A. Winnik, J. P. Pignol
and R. M. Reilly, Mol. Pharmaceutics, 2020, 17, 1226–1236.
49 A. Mesbahi, Reports Pract. Oncol. Radiother., 2010, 15,
176–180.
50 C. H. Chen, Y.-J. Wu and J.-J. Chen, Front. Biosci., Landmark
Ed., 2016, 21, 1211–1221.
51 X. Qu, C. Yao, J. Wang, Z. Li and Z. Zhang, Int. J. Nanomed.,
2012, 7, 6095–6103.
52 D. C. Zelasko-Leon, C. M. Fuentes and P. B. Messersmith,
PLoS One, 2015, 10, e0128756.
53 C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau,
S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren,
M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee and
D. Mukhopadhyay, Cancer Res., 2008, 68, 1970–1978.
54 J. Spadavecchia, D. Movia, C. Moore, C. M. Maguire,
H. Moustaoui, S. Casale, Y. Volkov and A. Prina-Mello,
Int. J. Nanomed., 2016, 11, 791–822.
55 A. Das, E. Soehnlen, S. Woods, R. Hegde, A. Henry,
A. Gericke and S. Basu, J. Nanopart. Res., 2011, 13, 6283–6290.
56 S. Tummala, M. N. S. Kumar and S. K. Pindiprolu, Drug
Delivery, 2016, 23, 3505–3519.
57 E. Cruz and V. Kayser, Cancers, 2019, 11, 870.
58 H. W. Kao, Y. Y. Lin, C. C. Chen, K. H. Chi, D. C. Tien,
C. C. Hsia, M. H. Lin and H. E. Wang, Bioorg. Med. Chem.
Lett., 2013, 23, 3180–3185.
59 D. Rades, C. Wolff, R. Nadrowitz, C. Breunig, S. E. Schild,
M. Baehre and B. Meller, Int. J. Radiat. Oncol., Biol., Phys.,
2009, 75, 1226–1231.
60 G. Niu, X. Sun, Q. Cao, D. Courter, A. Koong, Q.-T. Le,
S. Sam Gambhir and X. Chen, Clin. Cancer Res., 2010, 16,
2095–2105.
61 S. Shirvani-Arani, A. Bahrami-Samani, A. R. Jalilian,
A. Shirvani-Arani and M. Ghannadi-Maragheh, J. Label.
Compd. Radiopharm., 2012, 55, 103–107.
62 S. Bhattacharyya, R. Bhattacharya, S. Curley, M. A.
McNiven and P. Mukherjee, Proc. Natl. Acad. Sci. U. S. A.,
2010, 107, 14541–14546.
63 C. D. Austin, A. M. De Mazière, P. I. Pisacane, S. M. van
Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman and
R. H. Scheller, Mol. Biol. Cell, 2004, 15, 5268–5282.
64 A. M. Hommelgaard, M. Lerdrup and B. van Deurs, Mol.
Biol. Cell, 2004, 15, 1557–1567.
65 Z. Cai, S. Yook, Y. Lu, D. Bergstrom, M. A. Winnik,
J. P. Pignol and R. M. Reilly, Pharm. Res., 2017, 34, 579–590.
66 T. Liu, J. Tian, Z. Chen, Y. Liang, J. Liu, S. Liu, H. Li, J. Zhan
and X. Yang, Nanotechnology, 2014, 25, 345103.
67 G. Obaid, I. Chambrier, M. J. Cook and D. A. Russell,
Photochem. Photobiol. Sci., 2015, 14, 737–747.
68 T. Stuchinskaya, M. Moreno, M. J. Cook, D. R. Edwards and
D. A. Russell, Photochem. Photobiol. Sci., 2011, 10, 822–831.
69 G. J. Kim, S. R. Park, G. C. Kim and J. K. Lee, Plasma Med.,
2011, 1, 45–54.
70 M. Zhang, H. S. Kim, T. Jin and W. K. Moon, J. Photochem.
Photobiol., B, 2017, 170, 58–64.
71 S. Liang, C. Li, C. Zhang, Y. Chen, L. Xu, C. Bao, X. Wang,
G. Liu, F. Zhang and D. Cui, Theranostics, 2015, 5, 970–984.
72 O. Penon, M. J. Marı́n, D. A. Russell and L. Pérez-Garcı́a,
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